Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models.

Cecil A, Gentschev I, Adelfinger M, Dandekar T, Szalay AA.

Bioengineered. 2019 Dec;10(1):190-196. doi: 10.1080/21655979.2019.1622220.

PMID:
31142183
2.

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.

Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, Szalay AA.

Viruses. 2015 Jul 20;7(7):4075-92. doi: 10.3390/v7072811.

3.

Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.

Cecil A, Gentschev I, Adelfinger M, Nolte I, Dandekar T, Szalay AA.

Bioengineered. 2014 Sep-Oct;5(5):319-25. doi: 10.4161/bioe.32227.

4.

Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

Adelfinger M, Gentschev I, Grimm de Guibert J, Weibel S, Langbein-Laugwitz J, Härtl B, Murua Escobar H, Nolte I, Chen NG, Aguilar RJ, Yu YA, Zhang Q, Frentzen A, Szalay AA.

PLoS One. 2014 Aug 5;9(8):e104337. doi: 10.1371/journal.pone.0104337. eCollection 2014.

5.

Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains.

Stritzker J, Huppertz S, Zhang Q, Geissinger U, Härtl B, Gentschev I, Szalay AA.

J Virol. 2014 Oct;88(19):11556-67. doi: 10.1128/JVI.00681-14. Epub 2014 Jul 23.

6.

Oncolytic virotherapy of canine and feline cancer.

Gentschev I, Patil SS, Petrov I, Cappello J, Adelfinger M, Szalay AA.

Viruses. 2014 May 16;6(5):2122-37. doi: 10.3390/v6052122. Review.

7.

Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.

Weibel S, Hofmann E, Basse-Luesebrink TC, Donat U, Seubert C, Adelfinger M, Gnamlin P, Kober C, Frentzen A, Gentschev I, Jakob PM, Szalay AA.

J Transl Med. 2013 May 1;11:106. doi: 10.1186/1479-5876-11-106.

8.

Imaging of intratumoral inflammation during oncolytic virotherapy of tumors by 19F-magnetic resonance imaging (MRI).

Weibel S, Basse-Luesebrink TC, Hess M, Hofmann E, Seubert C, Langbein-Laugwitz J, Gentschev I, Sturm VJ, Ye Y, Kampf T, Jakob PM, Szalay AA.

PLoS One. 2013;8(2):e56317. doi: 10.1371/journal.pone.0056317. Epub 2013 Feb 18.

9.

Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy.

Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, Szalay AA.

Bioengineered. 2013 Mar-Apr;4(2):84-9. doi: 10.4161/bioe.22462. Epub 2012 Oct 23.

10.

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

Patil SS, Gentschev I, Adelfinger M, Donat U, Hess M, Weibel S, Nolte I, Frentzen A, Szalay AA.

PLoS One. 2012;7(10):e47472. doi: 10.1371/journal.pone.0047472. Epub 2012 Oct 16.

11.

Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.

Donat U, Weibel S, Hess M, Stritzker J, Härtl B, Sturm JB, Chen NG, Gentschev I, Szalay AA.

PLoS One. 2012;7(9):e45942. doi: 10.1371/journal.pone.0045942. Epub 2012 Sep 25.

12.

Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma.

Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, Macneill A, Szalay AA.

PLoS One. 2012;7(5):e37239. doi: 10.1371/journal.pone.0037239. Epub 2012 May 15.

13.

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.

Patil SS, Gentschev I, Nolte I, Ogilvie G, Szalay AA.

J Transl Med. 2012 Jan 4;10:3. doi: 10.1186/1479-5876-10-3. Review.

14.

Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapies.

Hess M, Stritzker J, Härtl B, Sturm JB, Gentschev I, Szalay AA.

J Transl Med. 2011 Oct 11;9:172. doi: 10.1186/1479-5876-9-172.

15.

Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.

Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA, Chen NG, Stritzker J, Lauer UM, Szalay AA.

PLoS One. 2011;6(7):e22069. doi: 10.1371/journal.pone.0022069. Epub 2011 Jul 11.

16.

Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines.

Heisig M, Frentzen A, Bergmann B, Galmbacher K, Gentschev I, Hotz C, Schoen C, Stritzker J, Fensterle J, Rapp UR, Goebel W.

BMC Microbiol. 2011 Jul 11;11:163. doi: 10.1186/1471-2180-11-163.

17.

Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice.

Stritzker J, Hill PJ, Gentschev I, Szalay AA.

Bioeng Bugs. 2010 Mar-Apr;1(2):139-45. doi: 10.4161/bbug.1.2.10286. Epub 2009 Oct 9.

18.

Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.

Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, von Hof JM, Krewer B, Tietze LF, Gentschev I, Szalay AA.

Cancer Gene Ther. 2011 Jan;18(1):42-52. doi: 10.1038/cgt.2010.49. Epub 2010 Sep 10.

19.

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA.

J Oncol. 2010;2010:736907. doi: 10.1155/2010/736907. Epub 2010 Jun 23.

20.

Enterobacterial tumor colonization in mice depends on bacterial metabolism and macrophages but is independent of chemotaxis and motility.

Stritzker J, Weibel S, Seubert C, Götz A, Tresch A, van Rooijen N, Oelschlaeger TA, Hill PJ, Gentschev I, Szalay AA.

Int J Med Microbiol. 2010 Nov;300(7):449-56. doi: 10.1016/j.ijmm.2010.02.004. Epub 2010 May 23.

PMID:
20547100
21.

Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.

Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, Raab V, Heisig M, Chen N, Yu YA, Stritzker J, Szalay AA.

J Biomed Biotechnol. 2010;2010:489759. doi: 10.1155/2010/489759. Epub 2010 Apr 1.

22.

Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression.

Galmbacher K, Heisig M, Hotz C, Wischhusen J, Galmiche A, Bergmann B, Gentschev I, Goebel W, Rapp UR, Fensterle J.

PLoS One. 2010 Mar 8;5(3):e9572. doi: 10.1371/journal.pone.0009572.

23.

Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.

Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA.

Cancer Gene Ther. 2009 Apr;16(4):320-8. doi: 10.1038/cgt.2008.87. Epub 2008 Oct 24.

PMID:
18949014
24.

Improvement of the live vaccine strain Salmonella enterica serovar Typhi Ty21a for antigen delivery via the hemolysin secretion system of Escherichia coli.

Hotz C, Fensterle J, Goebel W, Meyer SR, Kirchgraber G, Heisig M, Fürer A, Dietrich G, Rapp UR, Gentschev I.

Int J Med Microbiol. 2009 Feb;299(2):109-19. doi: 10.1016/j.ijmm.2008.06.006. Epub 2008 Aug 15.

PMID:
18706861
25.

Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.

Fensterle J, Bergmann B, Yone CL, Hotz C, Meyer SR, Spreng S, Goebel W, Rapp UR, Gentschev I.

Cancer Gene Ther. 2008 Feb;15(2):85-93. Epub 2007 Dec 14.

PMID:
18084243
26.

Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens.

Gentschev I, Spreng S, Sieber H, Ures J, Mollet F, Collioud A, Pearman J, Griot-Wenk ME, Fensterle J, Rapp UR, Goebel W, Rothen SA, Dietrich G.

Chemotherapy. 2007;53(3):177-80. Epub 2007 Mar 7.

PMID:
17347563
27.

Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.

Gentschev I, Fensterle J, Schmidt A, Potapenko T, Troppmair J, Goebel W, Rapp UR.

BMC Cancer. 2005 Feb 9;5:15.

28.

Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain.

Gentschev I, Dietrich G, Spreng S, Neuhaus B, Maier E, Benz R, Goebel W, Fensterle J, Rapp UR.

Int J Med Microbiol. 2004 Oct;294(6):363-71.

PMID:
15595386
29.

Growth, virulence, and immunogenicity of Listeria monocytogenes aro mutants.

Stritzker J, Janda J, Schoen C, Taupp M, Pilgrim S, Gentschev I, Schreier P, Geginat G, Goebel W.

Infect Immun. 2004 Oct;72(10):5622-9.

30.

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins.

Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA.

Nat Biotechnol. 2004 Mar;22(3):313-20. Epub 2004 Feb 8.

PMID:
14990953
31.

Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery.

Pilgrim S, Stritzker J, Schoen C, Kolb-Mäurer A, Geginat G, Loessner MJ, Gentschev I, Goebel W.

Gene Ther. 2003 Nov;10(24):2036-45.

PMID:
14566363
32.

Haemolysin A and listeriolysin--two vaccine delivery tools for the induction of cell-mediated immunity.

Dietrich G, Viret JF, Gentschev I.

Int J Parasitol. 2003 May;33(5-6):495-505. Review.

PMID:
12782050
33.

Deletion of the gene encoding p60 in Listeria monocytogenes leads to abnormal cell division and loss of actin-based motility.

Pilgrim S, Kolb-Mäurer A, Gentschev I, Goebel W, Kuhn M.

Infect Immun. 2003 Jun;71(6):3473-84.

34.

Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes.

Kolb-Mäurer A, Kämmerer U, Mäurer M, Gentschev I, Bröcker EB, Rieckmann P, Kämpgen E.

FEMS Immunol Med Microbiol. 2003 Apr 1;35(3):255-62.

36.

Efficient expression of the alpha-haemolysin determinant in the uropathogenic Escherichia coli strain 536 requires the leuX-encoded tRNA(5)(Leu).

Dobrindt U, Emödy L, Gentschev I, Goebel W, Hacker J.

Mol Genet Genomics. 2002 May;267(3):370-9. Epub 2002 Apr 26.

PMID:
12073039
37.

Delivery of protein antigens and DNA by attenuated intracellular bacteria.

Gentschev I, Dietrich G, Spreng S, Pilgrim S, Stritzker J, Kolb-Mäurer A, Goebel W.

Int J Med Microbiol. 2002 Feb;291(6-7):577-82. Review.

PMID:
11890559
38.

The E. coli alpha-hemolysin secretion system and its use in vaccine development.

Gentschev I, Dietrich G, Goebel W.

Trends Microbiol. 2002 Jan;10(1):39-45. Review.

PMID:
11755084
39.

Antibodies against listerial protein 60 act as an opsonin for phagocytosis of Listeria monocytogenes by human dendritic cells.

Kolb-Mäurer A, Pilgrim S, Kämpgen E, McLellan AD, Bröcker EB, Goebel W, Gentschev I.

Infect Immun. 2001 May;69(5):3100-9.

40.

Recombinant attenuated bacteria for the delivery of subunit vaccines.

Gentschev I, Dietrich G, Spreng S, Kolb-Mäurer A, Brinkmann V, Grode L, Hess J, Kaufmann SH, Goebel W.

Vaccine. 2001 Mar 21;19(17-19):2621-8.

PMID:
11257401
41.

Gram-positive and Gram-negative bacteria as carrier systems for DNA vaccines.

Dietrich G, Kolb-Mäurer A, Spreng S, Schartl M, Goebel W, Gentschev I.

Vaccine. 2001 Mar 21;19(17-19):2506-12.

PMID:
11257384
42.

Secretion of listeriolysin by Brucella suis inhibits its intramacrophagic replication.

Köhler S, Layssac M, Naroeni A, Gentschev I, Rittig M, Liautard JP.

Infect Immun. 2001 Apr;69(4):2753-6.

43.

From evil to good: a cytolysin in vaccine development.

Dietrich G, Hess J, Gentschev I, Knapp B, Kaufmann SH, Goebel W.

Trends Microbiol. 2001 Jan;9(1):23-8. Review.

PMID:
11166239
44.

Secretion of different listeriolysin cognates by recombinant attenuated Salmonella typhimurium: superior efficacy of haemolytic over non-haemolytic constructs after oral vaccination.

Hess J, Grode L, Gentschev I, Fensterle J, Dietrich G, Goebel W, Kaufmann SH.

Microbes Infect. 2000 Dec;2(15):1799-806.

PMID:
11165923
45.

Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis.

Spreng S, Gentschev I, Goebel W, Weidinger G, ter Meulen V, Niewiesk S.

Microbes Infect. 2000 Nov;2(14):1687-92.

PMID:
11137042
46.

Bacterial systems for the delivery of eukaryotic antigen expression vectors.

Dietrich G, Spreng S, Gentschev I, Goebel W.

Antisense Nucleic Acid Drug Dev. 2000 Oct;10(5):391-9. Review.

PMID:
11079578
47.

Delivery of protein antigens and DNA by virulence-attenuated strains of Salmonella typhimurium and Listeria monocytogenes.

Gentschev I, Dietrich G, Spreng S, Kolb-Mäurer A, Daniels J, Hess J, Kaufmann SH, Goebel W.

J Biotechnol. 2000 Sep 29;83(1-2):19-26.

PMID:
11000455
48.

Listeria monocytogenes-infected human dendritic cells: uptake and host cell response.

Kolb-Mäurer A, Gentschev I, Fries HW, Fiedler F, Bröcker EB, Kämpgen E, Goebel W.

Infect Immun. 2000 Jun;68(6):3680-8.

49.

Identification of immunogenic antigens of Helicobacter pylori via the Escherichia coli hemolysin secretion system(1).

Spreng S, Gentschev I, Goebel W, Mollenkopf H, Eck M, Müller-Hermelink HK, Schmausser B.

FEMS Microbiol Lett. 2000 May 15;186(2):251-6.

50.

Novel bacterial systems for the delivery of recombinant protein or DNA.

Spreng S, Dietrich G, Niewiesk S, ter Meulen V, Gentschev I, Goebel W.

FEMS Immunol Med Microbiol. 2000 Apr;27(4):299-304.

Supplemental Content

Loading ...
Support Center